Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

PSA updated: still relevant in the new millennium?

Shah JB, Reese AC, McKiernan JM, Benson MC.

Eur Urol. 2005 Apr;47(4):427-32. Epub 2005 Jan 12. Review. No abstract available.

PMID:
15774237
2.

PSA and prostate cancer screening: the challenge of the new millennium.

Bjartell A.

Eur Urol. 2007 Nov;52(5):1284-6. Epub 2007 Aug 21. No abstract available.

PMID:
17720305
3.

[PSA based screening for prostatic cancer].

Johansen TE.

Tidsskr Nor Laegeforen. 2008 Nov 20;128(22):2612-4. Norwegian. No abstract available.

4.

[About Psa-screening].

Hakama M, Auvinen A, Stenman UH, Tammela T.

Duodecim. 1996;112(14):1314-6. Finnish. No abstract available.

PMID:
10596108
5.

PSA screening.

Cohen S, Schiff S, Kelty P.

Med Health R I. 2005 Mar;88(3):90-1. Review. No abstract available.

PMID:
15915782
6.

[Biological markers of prostate cancer].

Seitz C, Djavan B.

Ann Urol (Paris). 2006 Dec;40(6):329-35. Review. French.

PMID:
17214230
7.

[PSA-screening: sensible or meaningless?].

Dubben HH.

Urologe A. 2009 Sep;48(9):1103; author reply 1103-4. doi: 10.1007/s00120-009-2112-3. German. No abstract available.

PMID:
19727645
8.

[Current role of PSA and other markers in the diagnosis of prostate cancer].

Gómez Veiga F, Ponce Reixa J, Barbagelata López A, Fernández Rosado E, Gonzaĺez Martiń M.

Arch Esp Urol. 2006 Dec;59(10):1069-82. Review. Spanish.

PMID:
17283720
9.

Prostate specific antigen (PSA)-based screening.

Suzuki H, Flanigan RC, Okuyama A; American Urological Association..

Int J Urol. 2008 Sep;15(9):757-62. doi: 10.1111/j.1442-2042.2008.02122.x. No abstract available.

10.

Update on PSA testing.

Gonzalgo ML, Carter HB.

J Natl Compr Canc Netw. 2007 Aug;5(7):737-42. Review.

PMID:
17692178
11.

Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer.

Schröder FH, Roobol MJ.

Curr Opin Urol. 2009 May;19(3):227-31. doi: 10.1097/MOU.0b013e328329a2d0. Review.

PMID:
19357513
12.

Prostate cancer in men with serum PSA of <4 ng/ml: under-diagnosed or over-treated?

Yossepowitch O.

Eur Urol. 2008 Apr;53(4):686-8. Epub 2007 Nov 6. No abstract available.

PMID:
17997025
13.

[PSA level--is 4.0 ng/ml as upper limit too high].

[No authors listed]

Aktuelle Urol. 2005 Jun;36(3):181-8. German. No abstract available.

PMID:
16001334
14.
15.

[The National Board of Health and Welfare's guidelines for prostatic cancer care. PSA test screening--only for well-informed men].

Bratt O, Damber JE, Kärvinge C, Malm T, Hensjö LO, Hyttsten E.

Lakartidningen. 2008 Feb 20-26;105(8):524-8. Swedish. No abstract available.

PMID:
18363292
16.

Prostate specific antigen.

Benson MC.

J Urol. 1997 Jun;157(6):2197-8. No abstract available.

PMID:
9146613
17.

Prostate-specific antigen (PSA) should drive doing prostate biopsies.

Loeb S, Catalona WJ.

Urol Oncol. 2012 Jan-Feb;30(1):1-2. doi: 10.1016/j.urolonc.2010.10.007. Epub 2011 Apr 1. No abstract available.

PMID:
21458316
18.

Point-of-care PSA testing: an evaluation of PSAwatch.

Karim O, Rao A, Emberton M, Cochrane D, Partridge M, Edwards P, Walker I, Davidson I.

Prostate Cancer Prostatic Dis. 2007;10(3):270-3. Epub 2007 Mar 13.

PMID:
17353914
19.

[Advantages and risks of the use of prostate-specific antigen (PSA) in the health-care area No. 4 of Gijon (Asturias)].

Cepeda Piorno J, Rivas del Fresno M, Fuente Martín E, González García E, Muruamendiaraz Fernández V, Fernández Rodríguez E.

Arch Esp Urol. 2005 Jun;58(5):403-11. Spanish.

PMID:
16078781
20.

[Elevated PSA--what to do?].

Machemer H, Rohde D.

MMW Fortschr Med. 2008 Oct 30;150(44):38-9. German. No abstract available.

PMID:
19024490

Supplemental Content

Support Center